Nineteen evaluable patients with advanced endometrial cancer refractory to one prior chemotherapeutic regimen were treated with a 5-day schedule of fludarabine phosphate. No responses were noted. The major toxicity was grade 2 or greater leukopenia in 45% of patients. Fludarabine phosphate at this dose and schedule does not appear to be an active agent for patients with refractory endometrial cancer.
|Original language||English (US)|
|Number of pages||2|
|Journal||American Journal of Clinical Oncology: Cancer Clinical Trials|
|State||Published - 1991|
ASJC Scopus subject areas
- Cancer Research